Role of Diacylglycerol Kinases in Acute Myeloid Leukemia
Diacylglycerol kinases (DGKs) play dual roles in cell transformation and immunosurveillance. According to cancer expression databases, acute myeloid leukemia (AML) exhibits significant overexpression of multiple DGK isoforms, including , and , without a precise correlation with specific AML subtypes...
Gespeichert in:
Veröffentlicht in: | Biomedicines 2023-07, Vol.11 (7), p.1877 |
---|---|
Hauptverfasser: | , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Diacylglycerol kinases (DGKs) play dual roles in cell transformation and immunosurveillance. According to cancer expression databases, acute myeloid leukemia (AML) exhibits significant overexpression of multiple DGK isoforms, including
,
and
, without a precise correlation with specific AML subtypes. In the TGCA database, high
expression negatively correlates with survival, while high
expression is associated with a more favorable prognosis.
and
also feature different patterns of co-expressed genes. Conversely, the BeatAML and TARGET databases show that high
expression is correlated with shorter survival. To assess the suitability of DGKs as therapeutic targets, we treated HL-60 and HEL cells with DGK inhibitors and compared cell growth and survival with those of untransformed lymphocytes. We observed a specific sensitivity to R59022 and R59949, two poorly selective inhibitors, which promoted cytotoxicity and cell accumulation in the S phase in both cell lines. Conversely, the DGKA-specific inhibitors CU-3 and AMB639752 showed poor efficacy. These findings underscore the pivotal and isoform-specific involvement of DGKs in AML, offering a promising pathway for the identification of potential therapeutic targets. Notably, the
and
isoforms emerge as relevant players in AML pathogenesis, albeit DGKA inhibition alone seems insufficient to impair AML cell viability. |
---|---|
ISSN: | 2227-9059 2227-9059 |
DOI: | 10.3390/biomedicines11071877 |